TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
SAN DIEGO, Dec. 16, 2010 /PRNewswire/ -- TriLink BioTechnologies (TriLink), a leading provider of custom nucleic acid-based products, today announced the launch of an innovative Hot Start solution for the PCR amplification of problematic GC-rich sequences, CleanAmp™ 7-deaza-dGTP.
When DNA targets high in GC-content are amplified, PCR product formation can often be compromised by inadequate strand separation and the propensity for complex secondary structure formation. The use of standard 7-deaza-dGTP is a notable method for overcoming this problem. TriLink has developed CleanAmp™ 7-deaza-dGTP, an elegant fusion of the secondary structure reducing nucleotide analog 7-deaza-dGTP and TriLink's CleanAmp™ dNTP Hot Start technology. CleanAmp™ 7-deaza-dGTP is available individually for amplification of routine GC-rich targets or as the CleanAmp™ 7-deaza-dGTP Mix which is recommended for more challenging targets with higher GC-content.
"Genetic disease diagnosis commonly involves the detection of GC-rich sequence elements, which have remained a stumbling block in the advancement of personalized medicine. CleanAmp™ 7-deaza-dGTP is our contribution to advancing this science. We hope it will become an invaluable tool," stated CEO, Richard Hogrefe.
"The amplification of bacteria with high GC-content, such as the pathogenic mycobacterium, is essential for the diagnosis of many deadly diseases such as tuberculosis and leprosy. CleanAmp™ 7-deaza-dGTP shows promise for the diagnosis of these diseases and the possibility for earlier treatment," stated Scientific Investigator, Natasha Paul.
Visit www.trilinkbiotech.com/cleanamp to learn more.
TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 75 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email firstname.lastname@example.org, or visit our web site at www.trilinkbiotech.com.
SOURCE TriLink BioTechnologies, Inc.